Shares of Abiomed Inc. plunged by nearly one-third on the Nasdaq stock exchange Thursday after the Danvers company said it is the subject of a federal investigation.

In documents filed with the Securities and Exchange Commission, the cardiac device maker disclosed it has received a subpoena from the US attorney’s office seeking files related to the labeling and marketing of its Impella 2.5 heart pump.